(TEVA) Teva Pharmaceuticals – Bull of the Day

January 21st, 2010

Teva Pharmaceuticals (TEVA) reported earnings of $0.89 in the third quarter of 2009, up 16% from the year-ago period and a cent above the Zacks Consensus Estimate. Net sales increased 25% to $3.55 billion.

We are impressed with Teva’s strong performance in the first nine months of 2009. We expect Teva to continue posting strong revenues and earnings going forward thanks to new product launches, both generic and branded. We are also pleased to see Teva’s progress with its branded and biogenerics pipeline. Biogenerics should help drive growth in the long-term.

Meanwhile, the acquisition of Barr should help Teva strengthen its position in the U.S. and expand its presence in Europe. We are maintaining our Outperform recommendation on Teva with a price target of $65.

Zacks Investment Research

More on this topic (What's this?)
The Complete List of Israeli Stocks Traded in the U.S. (Top Foreign Stocks, 12/6/09)
Teva Pharmaceutical: A Fair Price (Bullish Bankers, 3/11/10)
Thursday's Hot Stocks: Selling Time on Valeant Pharmaceuticals (Hot Trading Strategies For A Col..., 1/8/10)
Orphan Drugs Are Good! BioMarin Pharmaceuticals (Phil’s Stock World - Members S..., 1/27/10)
Read more on Pharmaceuticals, Teva Pharmaceutical Industries at Wikinvest


Similar Posts: | | Drug Manufacturers - Other | Healthcare

RSS feeds: TEVA | Teva Pharmaceutical Industries Limited | Drug Manufacturers - Other | Healthcare |

Other Posts by vitalstocks | RSS Feed for this author

Post a Response

You must be logged in to post a comment.